Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Dose-escalated brachytherapy best treatment for unfavourable-risk localised prostate cancer

Share :

2015 Genitourinary Cancers Symposium
Published: 26 Feb 2015
Views: 2974
Rating:
Save
Dr Scott Tyldesley - British Columbia Cancer Agency, Vancouver, Canada

Dr Tyldesley talks to ecancertv at ASCO GU 2015 about his work looking at dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) to treat men with unfavourable-risk localised prostate cancer.

Related Videos

Prostate cancer

Dr Alison Tree - Institute of Cancer Research, London, UK
Prostate cancer ( Dr Alison Tree - Institute of Cancer Research, London, UK )
22 Jan 2025

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard
Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )
15 Sep 2024

Adjuvant radiotherapy has no benefit following radical prostatectomy

Prof Noel Clarke - The Christie NHS Foundation Trust, Manchester, UK
Adjuvant radiotherapy has no benefit following radical prostatectomy ( Prof Noel Clarke - The Christie NHS Foundation Trust, Manchester, UK )
27 Oct 2023

Management of prostate cancer in Africa: Looking to the future

Dr Timothy Rebbeck - Dana-Farber Cancer Institute, Boston, USA
Management of prostate cancer in Africa: Looking to the future ( Dr Timothy Rebbeck - Dana-Farber Cancer Institute, Boston, USA )
25 May 2023

A single fractionated cycle of 225Ac-J591 shows preliminary efficacy on mCRPC patients

Dr Jones Nauseef - Weill Cornell Medicine, New York City, USA
A single fractionated cycle of 225Ac-J591 shows preliminary efficacy on mCRPC patients ( Dr Jones Nauseef - Weill Cornell Medicine, New York City, USA )
20 Apr 2023

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC

Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia
Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC ( Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia )
16 Mar 2023

Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery

Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany
Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )
16 Mar 2023

Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer

Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer ( Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK )
17 Feb 2023

Stereotactic body radiotherapy compared with surgery for localised prostate cancer

Dr Nicholas John van As - The Royal Marsden NHS Foundation Trust, London, UK
Stereotactic body radiotherapy compared with surgery for localised prostate cancer ( Dr Nicholas John van As - The Royal Marsden NHS Foundation Trust, London, UK )
16 Feb 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation